Zontivity® (Vorapaxar) Approved Last Week -- Albeit With A Very Narrow Label -- As We Predicted In 2012

My best guess is that -- after all these manifold, multi-year setbacks -- for the legacy Schering-Plough vorapaxar candidate, we will see peak annual sales under $200 million.

Sad to say, but likely so, given the winnowing of the indications -- driven by the data in the various clinical trials.

So I only make mention of it here, almost a week later. But do recall that the early February 2011 $1.7 billion writeoff was attributed in large part to this candidate's flagging profile of risk to efficacy, in the less severe cardio cases. Merck will brand it as Zontivity^®. Okay.

So it goes.